0
0
0
Drug Origin Transparency Act of 2023
2/5/2024, 2:30 PM
Summary of Bill HR 3810
Bill 118 HR 3810, also known as the Drug Origin Transparency Act of 2023, aims to increase transparency in the pharmaceutical industry by requiring drug manufacturers to disclose the origin of their products. The bill specifically targets drugs that are imported from foreign countries, requiring manufacturers to provide detailed information on where the drug was produced, processed, and packaged.
The legislation also mandates that drug manufacturers disclose any financial relationships they have with foreign entities involved in the production of the drug. This information is intended to help consumers make more informed decisions about the safety and quality of the medications they are taking.
Additionally, the Drug Origin Transparency Act of 2023 includes provisions to strengthen the oversight of drug imports, including increased inspections of foreign manufacturing facilities and stricter penalties for companies that fail to comply with the disclosure requirements. Overall, the bill seeks to improve transparency and accountability in the pharmaceutical industry, ultimately aiming to ensure the safety and efficacy of drugs imported into the United States.
The legislation also mandates that drug manufacturers disclose any financial relationships they have with foreign entities involved in the production of the drug. This information is intended to help consumers make more informed decisions about the safety and quality of the medications they are taking.
Additionally, the Drug Origin Transparency Act of 2023 includes provisions to strengthen the oversight of drug imports, including increased inspections of foreign manufacturing facilities and stricter penalties for companies that fail to comply with the disclosure requirements. Overall, the bill seeks to improve transparency and accountability in the pharmaceutical industry, ultimately aiming to ensure the safety and efficacy of drugs imported into the United States.
Read the Full Bill
Current Status of Bill HR 3810
Bill HR 3810 is currently in the status of Bill Introduced since June 5, 2023. Bill HR 3810 was introduced during Congress 118 and was introduced to the House on June 5, 2023. Bill HR 3810's most recent activity was Referred to the Subcommittee on Health. as of June 9, 2023
Bipartisan Support of Bill HR 3810
Total Number of Sponsors
1Democrat Sponsors
1Republican Sponsors
0Unaffiliated Sponsors
0Total Number of Cosponsors
8Democrat Cosponsors
8Republican Cosponsors
0Unaffiliated Cosponsors
0Policy Area and Potential Impact of Bill HR 3810
Primary Policy Focus
HealthPotential Impact Areas
- Consumer affairs
- Government information and archives
- Manufacturing
- Prescription drugs
Alternate Title(s) of Bill HR 3810
Drug Origin Transparency Act of 2023
Drug Origin Transparency Act of 2023
To amend the Federal Food, Drug, and Cosmetic Act to enhance drug manufacturing amount information reporting, and for other purposes.
Comments
Sponsors and Cosponsors of HR 3810
Latest Bills
Momnibus Act
Bill HR 7973April 2, 2026
Providing for consideration of the bill (H.R. 4922) to limit youth offender status in the District of Columbia to individuals 18 years of age or younger, to direct the Attorney General of the District of Columbia to establish and operate a publicly accessible website containing updated statistics on juvenile crime in the District of Columbia, to amend the District of Columbia Home Rule Act to prohibit the Council of the District of Columbia from enacting changes to existing criminal liability sentences, and for other purposes; providing for consideration of the bill (H.R. 5143) to establish standards for law enforcement officers in the District of Columbia to engage in vehicular pursuits of suspects, and for other purposes; providing for consideration of the bill (H.R. 5140) to lower the age at which a minor may be tried as an adult for certain criminal offenses in the District of Columbia to 14 years of age; providing for consideration of the bill (H.R. 5125) to amend the District of Columbia Home Rule Act to terminate the District of Columbia Judicial Nomination Commission, and for other purposes; providing for consideration of the bill (H.R. 1047) to require the Federal Energy Regulatory Commission to reform the interconnection queue process for the prioritization and approval of certain projects, and for other purposes; providing for consideration of the bill (H.R. 3015) to reestablish the National Coal Council in the Department of Energy to provide advice and recommendations to the Secretary of Energy on matters related to coal and the coal industry, and for other purposes; providing for consideration of the bill (H.R. 3062) to establish a more uniform, transparent, and modern process to authorize the construction, connection, operation, and maintenance of international border-crossing facilities for the import and export of oil and natural gas and the transmission of electricity; and for other purposes.
Bill HRES 707April 2, 2026
Halt Immigration from Countries with Inadequate Verification Capabilities Act
Bill HR 7964April 2, 2026
Don Young Doug LaMalfa Indian Buffalo Management Act
Bill HR 7954April 2, 2026
Closing the Enhanced Prudential Standards Loophole Act
Bill HR 7888April 2, 2026
SUPER BUGS Act of 2026
Bill HR 7879April 2, 2026
No Tax on Drill Pay Act
Bill HR 7897April 2, 2026
Respect for Essential Workers Act
Bill HR 7899April 2, 2026
PBM Kickback Prohibition Act
Bill HR 7895April 2, 2026
Long-Term Good Neighbor Authority Act
Bill HR 7951April 2, 2026
Protecting PAHPA Act of 2023
Bill HR 4697February 5, 2024